Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin

Journal of Drug Targeting

Volumn 24, Issue 1, 2016, Pages 68-79

  Pawar, Smita ^a   Vavia, Pradeep ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Docking study; doxorubicin; glucose transporter proteins; N lauryl glucosam; niosomes

Indexed keywords

CHOLESTEROL; DICETYL PHOSPHATE; DOXORUBICIN; GLUCORECEPTOR; GLUCOSAMINE DERIVATIVE; GLUCOSE TRANSPORTER; LAURIC ACID DERIVATIVE; N LAURYL GLUCOSAMINE; NANOCARRIER; NIOSOME; SORBITAN STEARATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUCOSAMINE; HEXOSE; LIPOSOME;

ARTICLE; B6F10 CELL LINE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG STABILITY; DRUG TARGETING; ELECTRICAL POTENTIAL PARAMETERS; ENTRAPMENT EFFICIENCY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTERNALIZATION; MELANOMA CELL LINE; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; NANOPHARMACEUTICS; PARTICLE SIZE; PRIORITY JOURNAL; X RAY DIFFRACTION; ZETA POTENTIAL; CHEMISTRY; DRUG RELEASE; MEDICINAL CHEMISTRY; SURFACE PROPERTY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DOXORUBICIN; DRUG LIBERATION; DRUG STABILITY; GLUCOSAMINE; HEXOSES; HUMANS; LIPOSOMES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84954523263     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1055572     Document Type: Article

References (49)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58
2. Si-Shen F, Shu C. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003; 58: 4087-114
3. Pereverzeva E, Treschalin I, Bodyagin D, et al. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity. Int J Pharm 2007; 337: 346-56
4. Aarif YK, Peter PL, Thomas F, et al. Cardiotoxicity due to cancer therapy. Cancer Heart 2011; 38: 253-9
5. Moorthi CR, Manavalan K, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharmaceut Sci 2011; 14: 67-77
6. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771-82
7. Yogeshkumar M, Marilena L, Alexander MS. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30: 592-9
8. Xiaowei D, Russell JM. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010; 5: 597-615
9. Frank G, Rohit K, Andrew W, et al. Targeted nanoparticles for cancer therapy. Nano Today 2007; 2: 14-21
10. Lara SJ, Lilian EV, Sunita Y, Mansoor MA. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008; 34: 592-602
11. Ruth D. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6: 688-701
12. Chris O, Wouter B, Mariska B, et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010; 27: 2569-89
13. Lilian EV, Mansoor MA. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006; 3: 205-16
14. Darandale SS, Vavia PR. Cyclodextrin-based nanosponges of curcumin: formulation and physicochemical characterization. J Incl phenom macrocycl Chem 2013; 75: 315-22
15. Uchegbu IF, Double JA, Kelland LR, et al. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Target 1996; 3: 399-409
16. John WP. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002; 4: 95-9
17. Carlotta M, Donatella P, Christian C, et al. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J Control Release 2010; 147: 127-35
18. Marzio LD, Marianecci C, Cinque B, et al. pH-sensitive non-phospholipid vesicle and macrophage-like cells: binding, uptake and endocytotic pathway. Biochim Biophys Acta 2008; 1778: 2749-56
19. Jain CP, Vyas SP. Preparation and characterization of niosomes containing rifampicin for lung targeting, J Microencapsul 1995; 12: 401-7
20. Pawar SK, Badhwar AJ, Kharas F, et al. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery. Int J Pharm 2012; 436: 183-93
21. Johanna C, Christiane BH, Jacques P. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2010; 14: 771-94
22. Warburg O, Posener K, Negelein E. The metabolism of the carcinoma cell. In: Warburg O, ed. The metabolism of tumors. New York: Richard Smith, Inc.; 1931: 29-169
23. Taizo Y, Yutaka S, Hirofumi F, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-30
24. Uchegbu IF. The biodistribution of novel 200 nm palmitoyl muramic acid vesicles. Int J Pharm 1998; 162: 19-27
25. Jianing Q, Ping Y, Fen H, et al. Nanoparticles with dextran/chitosan shell and BSA/chitosan core-doxorubicin loading and delivery. Int J Pharm 2010; 393: 176-84
26. Brownlie A, Uchegbu IF, Schatzlein AG. PEI-based vesicle-polymer hybrid gene delivery system with improved biocompatibility. Int J Pharm 2004; 274: 41-52
27. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006; 1: 1112-16
28. Rao MV, Atreyi M, Rajeswar MR. Fluorescence studies on concanavalin-A. J Biosci 1984; 6: 823-8
29. Froehlich P. Understanding the sensitivity specification of spectrofluorometers. Int Lab 1989; 19: 42-5
30. Chipman DM, Grisaro V, Sharon N. The binding of oligosaccharides containing N-acetylglucosamine and N-acetylmuramic acid to lysozyme. The specificity of binding subsites. J Biol Chem 1967; 242: 4388-94
31. Wu G, Robertson DH, Brooks CL, Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 2003; 24: 1549-62
32. Glide, version 5.8, Schrödinger, LLC, New York, NY; 2012
33. Maestro, version 9.3, Schrödinger, LLC, New York, NY; 2012
34. Okimoto N, Futatsugi N, Fuji H, et al. High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. PLoS Comput Biol 2009; 5: 1-12
35. Kandasamy R, Veintramuthu S. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech 2010; 11: 1119-27
36. You HB, Kinam P. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011; 153: 198-205
37. Sahin NO. Niosomes as nanocarrier systems. In: Mozafari MR, ed. Nanomaterials and nanosystems for biomedical applications. Netherlands: Springer; 2007: 67-81
38. Al-Hamidi H, Edwards AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B 2010; 76: 170-8
39. US2011/0243851. Glucose PEG conjugate for reducing glucose transport into the cell
40. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-30
41. Schlick KH, Lange CK, Gillispie GD, Cloninger MJ. Characterization of protein aggregation via intrinsic fluorescence lifetime. J Am Chem Soc 2009; 131: 16608-9
42. Sha Z, Shiladitya B, William C, et al. Leucine-aspartic acid-valine sequence as targeting ligand and drug carrier for doxorubicin delivery to melanoma cells: in vitro cellular uptake and cytotoxicity studies. Pharmaceut Res 2009; 26: 2578-87
43. Dorit G, Aviva TH, Dina T, et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000; 6: 1949-57
44. Eksborg S. Extraction of daunorubicin and doxorubicin and their hydroxyl metabolites: self-association in aqueous solution. J Pharm Sci 1978; 67: 782-5
45. Mennozi M, Valentini L, Vannini E, Arcamone F. Self-association of doxorubicin and related compounds in aqueous solution. J Pharm Sci 1984; 73: 766-70
46. Takafumi M, Eriko T, Yuji K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001; 42: 1551-5
47. Raffaele C, Agnese V, Cristina R, et al. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol 2008; 291: 57-62
48. Thomas AH, Robert BM, Richard AF, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004; 47: 1750-9
49. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47: 1739-49